---
type: claim
domain: health
description: "RadNet's AI mammography study shows 36% of women paying $40 out-of-pocket for AI screening with 43% higher cancer detection, suggesting consumer demand will drive AI adoption faster than CMS reimbursement codes"
confidence: likely
source: "Bessemer Venture Partners, State of Health AI 2026 (bvp.com/atlas/state-of-health-ai-2026)"
created: 2026-03-07
---

# consumer willingness to pay out of pocket for AI-enhanced care is outpacing reimbursement creating a cash-pay adoption pathway that bypasses traditional payer gatekeeping

The conventional assumption in healthcare AI is that adoption requires reimbursement — if CMS doesn't create a CPT code and payers don't cover it, the technology stalls. RadNet's mammography study demolishes this assumption with the largest real-world evidence dataset to date.

**The RadNet evidence (747,604 women):**
- 36% of women offered AI-enhanced mammography chose to pay $40 out-of-pocket for it
- AI-enhanced screening detected cancer 43% more often than standard screening
- Overall cancer detection rate was 21% higher with AI
- Positive predictive value for cancer was 15% higher

The significance isn't just the clinical improvement — it's that more than a third of patients voluntarily paid a premium for AI-enhanced care when given the choice. This establishes a cash-pay adoption pathway that bypasses the traditional reimbursement bottleneck entirely.

This pattern is accelerating beyond imaging. Function Health reached $100M+ ARR in under two years selling $499/year comprehensive lab testing directly to consumers — no insurance involvement. ChatGPT Health reports 40 million+ daily users, with 1 in 5 asking health-related questions weekly. The consumer is pulling AI into healthcare faster than the payment system can accommodate it.

The structural implication: healthcare AI adoption will follow a dual-track model. Track 1 (reimbursement-dependent) moves at CMS speed — years of pilot programs, category III CPT codes, payment experiments. Track 2 (consumer cash-pay) moves at consumer technology speed — months to adoption, driven by demonstrated clinical value and willingness to pay. Track 2 will establish the use cases and evidence base that eventually forces Track 1 to follow.

Since [[the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification]], the regulatory framework already enables consumer-direct health AI without full medical device classification — removing one of the two traditional gatekeepers (FDA and CMS) from the adoption pathway.

The risk: cash-pay adoption creates a two-tier system where AI-enhanced care accrues to those who can afford the premium. This is the equity tension in consumer-led health innovation — early access is wealth-stratified until reimbursement catches up.

---

Relevant Notes:
- [[the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification]] — regulatory framework enabling consumer-direct health AI
- [[Function Health drives down diagnostic conversion costs to 499 per year for 100-plus lab tests making atoms-to-bits health data generation accessible at consumer scale]] — another cash-pay model bypassing traditional reimbursement
- [[AI diagnostic triage achieves 97 percent sensitivity across 14 conditions making AI-first screening viable for all imaging and pathology]] — the clinical capability that makes consumer willingness-to-pay rational
- [[healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care]] — consumer cash-pay could either accelerate the Jevons paradox (more diagnosis → more treatment) or enable prevention-first models depending on what consumers choose to buy

Topics:
- [[_map]]
